

Heterogeneity of PD-MCI in candidates to subthalamic deep brain stimulation: associated cortical and subcortical modifications

Quentin Devignes, Sami Daoudi, Romain Viard, Renaud Lopes, Nacim Betrouni, Gregory Kuchcinski, Anne-Sophie Rolland, Caroline Moreau, Luc Defebvre, Eric Bardinet, et al.

▶ To cite this version:

Quentin Devignes, Sami Daoudi, Romain Viard, Renaud Lopes, Nacim Betrouni, et al.. Heterogeneity of PD-MCI in candidates to subthalamic deep brain stimulation: associated cortical and subcortical modifications. Journal of Parkinson's disease, 2022, 12 (5), pp.1507-1526. 10.3233/JPD-223232. hal-03720928

HAL Id: hal-03720928 https://hal.science/hal-03720928

Submitted on 12 Jul2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Heterogeneity of PD-MCI in candidates to subthalamic deep brain stimulation: associated cortical and subcortical modifications

Quentin Devignes, PhD^{1#}, Sami Daoudi, MSc^{1#}, Romain Viard, PhD², Renaud Lopes, PhD², Nacim Betrouni, PhD¹, Gregory Kuchcinski, MD, PhD², Anne-Sophie Rolland, PhD³, Caroline Moreau, MD, PhD¹, Luc Defebvre, MD, PhD¹, Eric Bardinet, PhD⁴, Marie Bonnet, MSc⁵, Christine Brefel-Courbon, MD, PhD⁶, Christine Delmaire, MD, PhD⁷, Fouzia El Mountassir, MSc⁸, Frédérique Fluchère, MD⁹, Anne Fradet, MSc¹⁰, Caroline Giordana, MD¹¹, Elodie Hainque, MD¹², Jean-François Houvenaghel, PhD¹³, Béchir Jarraya, MD, PhD¹⁴, Hélène Klinger, MSc¹⁵, David Maltête, MD, PhD¹⁶, Ana Marques, MD, PhD¹⁷, Mylène Meyer, PhD¹⁸, Olivier Rascol, MD, PhD¹⁹, Tiphaine Rouaud, MD, PhD²⁰, Melissa Tir, MD, PhD²¹, Thomas Wirth, MD²², Jean-Christophe Corvol, MD, PhD¹², David Devos, MD, PhD^{1,3}, Kathy Dujardin, PhD^{1*} for the PREDISTIM working group

#These authors share first authorship

¹Univ. Lille, Inserm, Lille Neurosciences and Cognition, CHU-Lille, Neurology and Movement Disorders department, NS-Park/F-CRIN, Lille, France

² Univ. Lille, CNRS, Inserm, US 41 – UMS 2014 – PLBS, CHU Lille, Lille Pasteur Institute, Lille, France

³ Univ. Lille, Inserm, Lille Neurosciences and Cognition, CHU-Lille, Department of Medical Pharmacology, NS-Park/F-CRIN, Lille, France

⁴ Institut du Cerveau (ICM), Centre de Neuro-Imagerie de Recherche (CENIR), UMR S 1127, CNRS UMR 7225, Sorbonne Université, Paris, France

⁵ Centre Expert Parkinson, NS-Park/F-CRIN, Centre Mémoire de Ressources et de Recherche, IMNc, Hôpital Pellegrin, CHU de Bordeaux, France ⁶ Service de Neurologie B8, Centre Expert Parkinson, NS-Park/F-CRIN, Hôpital Pierre Paul Riquet, CHU Purpan, Toulouse, France

⁷ Department of Radiology, NS-Park/F-CRIN, Hôpital Fondation A de Rothschild, Paris, France
⁸ Université Paris-Saclay, CEA, CNRS, Baobab, Neurospin, Gif-sur-Yvette, France and Institut du Cerveau (ICM), UMR S 1127, CNRS UMR 7225, Sorbonne Université, Paris, France
⁹ Department of Neurology, NS-Park/F-CRIN, Assistance Publique - Hôpitaux de Marseille (APHM), Timone University Hospital and Institut de Neurosciences de la Timone, Marseille, France
¹⁰ Neurology Department, NS-Park/F-CRIN, University Hospital of Poitiers and INSERM, University of Poitiers, Centre d'Investigation Clinique CIC 1402, Poitiers, France
¹¹ Department of Neurology, NS-Park/F-CRIN, Centre Hospitalier Universitaire de Nice, Nice, France
¹² Sorbonne Université, Paris Brain Institute – ICM, NS-Park/F-CRIN, Assistance publique Hôpitaux

de Paris, Inserm, CRNS, Hôpital Pitié-Salpêtrière, Department of Neurology, Paris, France

¹³ Department of Neurology, NS-PARK/F-CRIN, University Hospital of Rennes, Rennes, France

¹⁴ Neuroscience Pole, NS-Park/F-CRIN, Hôpital Foch, Suresnes, University of Versailles Paris-Saclay, INSERM-CEA NeuroSpin, Saclay, France

¹⁵ Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, NS-Park/F-CRIN, Lyon, France

¹⁶ Department of Neurology, NS-Park/F-CRIN, Rouen University Hospital and University of Rouen, France; INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, France

¹⁷ Université Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand University Hospital, Neurology department, NS-Park/F-CRIN, Clermont-Ferrand, France
¹⁸ Neurology department, NS-Park/F-CRIN, Central Hospital, CHRU-Nancy, Nancy, France
¹⁹ Department of Clinical Pharmacology and Neuroscience, NS-Park/F-CRIN, Toulouse University Hospital, Toulouse, France ²⁰ Centre Expert Parkinson, NS-Park/F-CRIN, department of neurology, CHU Nantes, Nantes, France
²¹ Department of Neurology, NS-PARK/FCRIN, Amiens University Hospital, Amiens, France
²² Service de Neurologie, NS-Park/F-CRIN, Hôpitaux Universitaires de Strasbourg et Fédération de Médecine Translationnelle de Médecine de Strasbourg, Strasbourg, France ; Institut de Génétique et de Biologie Moléculaire et Cellulaire, INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France

*Corresponding author: Kathy Dujardin, Neurologie et pathologies du mouvement, Hôpital Salengro, CHU Lille, Rue Emile Laine, 59037 Lille Cedex, France Tel: + 33 320 44 67 52 Fax: +33 320 44 66 80 kathy.dujardin@univ-lille.fr

Running title: PD-MCI and subthalamic deep brain stimulation

Word counts

Title: 126 characters Abstract: 232/250 words Manuscript: 4419 words Running title: 45 characters Illustrations: 5 tables and 4 figures

ABSTRACT

<u>Background</u>: Parkinson's disease mild cognitive impairment (PD-MCI) is frequent and heterogenous. There is no consensus about its influence on subthalamic deep brain stimulation (STN-DBS) outcomes. <u>Objectives</u>: To determine the prevalence of PD-MCI and its subtypes in candidates to STN-DBS. Secondarily, we sought to identify MRI structural markers associated with cognitive impairment in these subgroups.

<u>Methods</u>: Baseline data from the French multicentric PREDISTIM cohort were used. Candidates to STN-DBS were classified according to their cognitive performance in normal cognition (PD-NC) or PD-MCI. The latter included frontostriatal (PD-FS) and posterior cortical (PD-PC) subtypes. Betweengroup comparisons were performed on demographical and clinical variables as well as on T1-weighted MRI sequences at the cortical and subcortical levels.

<u>Results</u>: 320 patients were included: 167 (52%) PD-NC and 153 (48%) PD-MCI patients. The latter group included 123 (80%) PD-FS and 30 (20%) PD-PC patients. There was no between-group difference regarding demographic and clinical variables. PD-PC patients had significantly lower global efficiency than PD-FS patients and significantly worse performance on visuospatial functions, episodic memory and language. Compared to PD-NC, PD-MCI patients had cortical thinning and radiomicbased changes in the left caudate nucleus and hippocampus. There were no significant differences between the PD-MCI subtypes.

<u>Conclusion</u>: Among the candidates to STN-DBS, a significant proportion has PD-MCI which is associated with cortical and subcortical alterations. Some PD-MCI patients have posterior cortical deficits, a subtype known to be at higher risk of dementia.

Keywords

Cortical thickness, radiomics, voxel-based morphometry, shape analysis, dual syndrome hypothesis

INTRODUCTION

Subthalamic deep brain stimulation (STN-DBS) is a common therapeutic surgical procedure for patients with advanced Parkinson's disease (PD) and with symptoms whose control by medical treatments fails. Even though various adverse effects have been reported, the efficacy of STN-DBS is established at short and longer term (for a review, see[1]). Improvement in motor symptoms is substantial and dopaminergic medication is significantly reduced, even several years after surgery [1]. Improvement in activities of daily living is observed up to five years and is more variable thereafter. Quality of life improves at short term, but improvement is lost quite rapidly (for a review, see [1]). The effects on non-motor symptoms are more variable. Regarding cognition, STN-DBS is generally considered as safe [2–4] even though a reduction in verbal fluency with an impact on communication satisfaction is systematically reported. The rate of dementia several years after STN-DBS seems similar as that observed in non-operated patients [4,5]. Besides the accuracy of the active contacts localization, existing studies agree on the need to identify the preoperative factors associated with a better long-term outcome.

Currently, low L-dopa sensitivity of axial symptoms, age over 70 years, PD dementia and unstable neuropsychiatric disorders are considered as contraindications to STN-DBS [6]. Among the selected patients, some have mild cognitive impairment (PD-MCI). Only few studies have investigated the role of PD-MCI on the long-term outcome of DBS in general [7,8] and of STN-DBS in particular [5,9,10]. In these latest studies, the prevalence of PD-MCI at baseline ranged from 23 to 76%. At follow-up, conversion to dementia was more frequent or earlier in patients with PD-MCI at baseline compared to patients with normal cognition. However, the study populations and methods varied from one study to the other. PD-MCI subtypes were considered in only one study that distinguished amnestic vs non-amnestic PD-MCI without finding differences at follow-up [5]. Cognitive decline can affect one single domain or be present across multiple domains [11]. Moreover, the affected domains vary and impairment in memory, visuospatial functions or language has been associated to a higher risk to

develop dementia earlier [12,13]. The "dual syndrome hypothesis" has been proposed to describe this heterogeneity by distinguishing, on the one hand, patients with a non-dopamine-mediated posterior cortical syndrome characterized by deficits in language, visuospatial functions and/or episodic memory and, on the other hand, patients with a dopamine-mediated frontostriatal syndrome characterized by deficits in executive functions, working memory and/or attention [14]. The follow-up of an incident PD cohort suggests that patients with a posterior cortical syndrome would have a faster progression to dementia than patients with a frontostriatal syndrome [15–17]. This heterogeneity has never been considered in the context of STN-DBS. Though, the issue is crucial. Indeed, even if having PD-MCI is not a contraindication to STN-DBS, certain subtypes seem to be more at risk of bad cognitive outcome in the short or medium term. Screening for them and determining whether they are associated with specific structural characteristics seem essential.

The main aim of the present study was to characterize the cognitive status of PD patients, candidates to STN-DBS, in order to determine the prevalence of PD-MCI and of its subtypes according to the dual syndrome hypothesis. The secondary objective was to identify MRI structural markers associated with the different cognitive subgroups.

Our hypothesis was that a certain proportion of PD patients, selected for STN-DBS, had PD-MCI, including posterior cortical deficits. We expected specific structural alterations associated with the PD-MCI subtypes.

MATERIALS AND METHODS

Patients

PD patients, candidates to STN-DBS, were included in PREDISTIM¹, an ongoing prospective, multicentric cohort study sponsored by the University Hospital of Lille, conducted in 17 PD excellence centers from the clinical research network in France (NS-Park/F-Crin), approved by the CPP Nord

¹ Predictive Factors and Subthalamic Stimulation in Parkinson's Disease

Ouest-IV Ethical Committee (CPP 2013-A00193-42) and registered in the ClinicalTrials.gov website (NCT02360683). The objective of PREDISTIM is to identify risk factors of disease progression after STN-DBS in PD. Briefly, patients undergoing STN-DBS in one of the participating centers were consecutively included into the study between 11/2013 and 09/2019. Inclusion criteria were a diagnosis of PD according to the UK Brain Bank diagnostic criteria for PD [18], disease duration \geq 5 years, age between 18 and 75 years and indication of STN-DBS. Exclusion criteria were atypical parkinsonism, severe cognitive impairment, severe psychiatric disorders, levodopa motor response lower than 30% and contra-indications to surgery. All participants gave informed written consent. Data collection was compliant with general data protection regulation rules.

In this ancillary study, we included only baseline data collected from participants in PREDISTIM who underwent a complete comprehensive neuropsychological assessment according to the consensus assessment procedure described below and 3T MRI scan.

Demographic and clinical variables

Sex, age, level of education, disease duration and age at onset were recorded. The Movement Disorder Society-Unified Parkinson's disease rating scale (MDS-UPDRS, section 1 to 4) was used to measure the severity of non-motor and motor symptoms [19]. MDS-UPDRS-3 scores were collected in the OFF-drug and best-ON conditions during a standardized acute levodopa challenge. Dopasensitivity was computed from these scores using the following formula: (OFF – best-ON)/OFF*100. The items of the MDS-UPDRS-3 scored at the left and the right side in the OFF condition were used to determine the dominant side of motor symptoms. Based on the sum for each side, a ratio (Left-Right)/(Left+Right) was calculated. A negative ratio indicated a right dominance of the motor symptoms, a positive one a left dominance and 0 no dominant side. Hoehn and Yahr staging was used to define disease severity [20]. Motor disability with/without treatment was assessed with the Schwab and England scale [21]. Quality of life was assessed by the Parkinson's disease questionnaire-39

(PDQ39) [22]. Depression, anxiety, and apathy were assessed using the Hamilton depression rating scale [23], the Hamilton anxiety rating scale [24] and the Lille apathy rating scale [25], respectively. L-Dopa equivalent daily dosage was calculated using a modified version of the algorithm developed by Tomlinson et al. [26]. The frequency of patients taking antipsychotic, antidepressant and anxiolytic medications was also recorded.

Cognitive assessment and subtyping

A consensus assessment procedure [27] meeting the MDS recommendations [28] for checking PD-MCI - level 2 criteria was adopted [11] for this ancillary study. Overall efficiency was assessed by the score at the Montreal Cognitive Assessment (MoCA) [29] and five cognitive domains (attention/working memory, executive functions, episodic memory, visuospatial functions, and language) were assessed with at least two tests by domain (details are shown in Table 2). A test was considered failed if the z-score on at least one test variable was \leq -1. Moreover, a cognitive domain was considered impaired when two tests in that domain were failed. Patients were classified as having normal cognition (PD-NC) or PD-MCI based on the clinical observation of the absence/presence of cognitive decline not sufficient to interfere significantly with functional independence and absence/presence of significant deficits on at least one cognitive domain. Within the PD-MCI group, we distinguished: (a) patients with frontostriatal subtype (PD-FS), i.e. deficits in attention/working memory and/or executive functions only, and (b) patients with at least posterior cortical subtype (PD-PC), i.e. deficits in visuospatial functions, memory and/or language isolated or in association with attention/working memory and/or executive deficits. To be able to distinguish subtypes according to the dual syndrome hypothesis, we were forced to slightly adapt the consensus MDS criteria for PD-MCI according to which deficits concern either two tests in one cognitive domain or one test in two different cognitive domains.

MRI acquisition

The imaging protocol included an anatomical three-dimensional T1-weighted sequence (3DT1) on 3T scanners using the similar parameters in all sites: voxel size:1x1x1 mm³; repetition time:7.03ms; echo time:3.18ms; matrix size:256x256x176 voxels; FA:9°.

The harmonization of inter-site imaging protocol along with the collection and quality control of acquired MRI data were performed by the center for imaging acquisition and treatment (CATI) [30], a platform dedicated to multicenter neuroimaging. All 3DT1 sequences were reviewed and scored from 0 (bad quality) to 4 (excellent quality). For the present study, imaging data with quality evaluation strictly lower than 2 were excluded.

MRI pre-processing

3DT1 images were processed using the Human Connectome Project pipeline in the software workbench 1.4.2 [31]. This optimized processing pipeline includes steps for non-uniform signal correction, signal and spatial normalizations, skull stripping based on the Freesurfer software (version 6.0, Massachusetts General Hospital, Boston, MA; <u>https://surfer.nmr.mgh.harvard.edu/</u>) and then provides parcellations and registrations using up-to-date libraries.

Subcortical MRI analyses

Segmentation of subcortical structures – Segmentation of bilateral caudate nuclei, thalami and hippocampi was performed online with volBrain, an automated MRI brain volumetry tool (<u>https://volbrain.upv.es</u>) [32]. Then, the masks were visually checked and manually corrected by a trained operator in their native space using Freeview 5.3 (<u>http://surfer.nmr.mgh.harvard.edu</u>). These masks were used as inputs for the volumetric, shape and radiomic analyzes. The same operation was applied to the Montreal Neurological Institute (MNI) 152 template to obtain an explicit mask with the 6 structures for voxel-based morphometry.

Volumetric analysis – Volume of each subcortical structure was computed with volBrain [32]. The total intracranial volume was also extracted.

Subcortical voxel-based morphometry – Preprocessed 3DT1 images were spatially normalized into the MNI152 space. Thereafter, the MNI152-based explicit mask was applied to extract the grey matter of our six subcortical structures from each 3DT1 image. The obtained volumes were finally smoothed with a 3-mm full width at half maximum Gaussian kernel prior to voxel-wise statistical analysis. Voxel-wise comparisons were performed within the MNI152-based explicit mask.

Shape analysis – Shape analysis of each subcortical structure was performed using the SPHARM-PDM method [33] in 3DSlicer (*www.slicer.org*) via the SlicerSALT project [34]. Manually corrected masks from volBrain [32] were used as inputs and converted to a spherical harmonic description (SPHARM), which was then sampled into a triangulated mesh (SPHARM-PDM). Fifteen harmonics were computed to obtain the best compromise between mesh smoothness and precision, thus generating 1,002 corresponding vertices on each surface. For each structure, meshes were aligned and spatially normalized with the mesh of the first patient using a rigid-body Procustes alignment. The quality of the meshes was visually assessed with the ShapePopulationViewer tool. For each patient and for each subcortical structure, a three-dimensional matrix containing spatial coordinates (x,y,z) was extracted from the mesh and used for statistical comparisons.

Analysis of radiomic features – After bias field correction, radiomic features were extracted from 3DT1 sequences with the open-source package Pyradiomics [35] using the manually corrected masks. First-order radiomic features were directly calculated from normalized grey levels for each subcortical structure, namely median, interquartile range, kurtosis (measures the "peakedness" of the distribution of voxel values) and skewness (measures the asymmetry of the distribution of voxel values about the mean). Second-order radiomic features were also calculated from grey level co-occurrence matrices in 3DT1 MRI sequences [36]. These matrices are second-order histograms, which capture spatial

relationships between voxels with predefined intensities in different directions (here, 26 connected directions) and with a predefined distance between voxels (here, the distance was set at 1 voxel). Thereafter, for each subcortical structure, seven second-order statistics were computed: inverse difference and normalized inverse difference moment (measure the local homogeneity of an image), contrast (measures the local intensity variation of voxel values), difference entropy (measures the randomness in neighborhood intensity value differences), correlation (measures the dependency of grey level values to their respective voxels in grey level co-occurrence matrices), difference variance (measures the heterogeneity of voxel intensity values and attributes higher weights to pairs, whose intensity level deviates more from the mean) and sum average (measures the relationship between occurrences of pairs with lower intensity values and occurrences of pairs with higher intensity values).

Cortical thickness analysis

For each vertex, cortical thickness was calculated in 3DT1 preprocessed images using a surface-based approach [37]. After automatic segmentation, cortical masks were systematically checked and manually corrected. Cortical thickness maps (32k vertices) were smoothed with a 15-mm full width at half maximum Gaussian kernel. The global average thickness for both hemispheres was also computed as a measure of global atrophy [38].

Statistical analyses

Demographic and clinical variables were reported as mean (standard deviation) for continuous variables and frequency (percentage) for categorical variables. They were compared between PD-NC and PD-MCI on the one hand and between PD-FS and PD-PC on the other hand using Mann-Whitney's U test for numerical variables and Fisher's exact test for categorical variables, with the R software version 4.0.4 [39]. Cognitive variables were compared using ANCOVA with permutation test (number of permutations = 10,000) controlling for age, sex, and level of education with the R package *permuco*

version 1.1.0 [40]. The mean z-score of a cognitive domain was computed by averaging the z-scores from the test variables that assessed this domain.

Regarding MRI parameters, ANCOVA with permutation test (number of permutations = 10,000) was used to compare PD-NC and PD-MCI groups with age, sex, level of education and center of recruitment as covariates. In case of significant result, comparison between PD-FS and PD-PC was performed within the concerned subcortical structures or cortical clusters. For all analyses, correction for multiple comparisons was applied with a false discovery rate (FDR) [41] fixed at 0.05. Finally, Spearman's partial correlation coefficients were computed between significant MRI measures and mean z-scores for each cognitive domain, controlling for age, sex, level of education and center, with the R package *ppcor* [42].

More precisely, volumes, radiomic features and mean cortical thickness with the R package *permuco* [40]. For voxel-based morphometry and vertex-wise cortical thickness, it was performed with the permutation analysis linear model (PALM) in the FMRIB software library (FSL 5.0.11) [43]. In addition, shape analysis was performed on the 3-dimensional matrices using MANCOVA with permutation test, with the R package *geomorph* version 3.3.2 [44]. Furthermore, it is noteworthy that subcortical volumes were normalized with the total intracranial volume computed with volBrain [32] to account for brain size differences between subjects. Likewise, voxel-based morphometry analyses were adjusted with the total intracranial volume using a proportional scaling approach with PALM [43]. For cortical thickness, information about significant clusters of cortical thinning were extracted using workbench 1.4.2 [31] with a minimum surface set at 20mm². Finally, Spearman's partial correlation coefficients were computed between significant MRI measures and mean z-scores for each cognitive domain, controlling for age, sex, level of education and center, with the R package *ppcor* [42].

RESULTS

The ancillary study flowchart is presented in **Figure 1.** After exclusion of patients with missing or inconsistent data, 320 patients were included. Based on their performance at the neuropsychological test battery, 167 (52%) were classified as PD-NC patients and 153 (48%) as PD-MCI patients (**Figure 2A**). Moreover, within the PD-MCI group, 123 (80%) had a PD-FS subtype and 30 (20%) a PD-PC subtype (**Figure 2A**).

Demographic and clinical variables

Demographic and clinical characteristics are shown in **Table 1**. No imputation for missing data was used since only 1.58% of data were missing. Population's main characteristics were: mean age = $60.03 (\pm 7.69)$ years; 203 (63%) men; mean disease duration = $9.72 (\pm 3.85)$ years; mean MDS-UPDRS 3 total score = $9.67 (\pm 7.51)$ in the Best-ON-medication state and $39.84 (\pm 15.94)$ in the off-medication state; mean Hoehn and Yahr stage = $1.25 (\pm 0.79)$ on-medication and $2.58 (\pm 0.87)$ off-medication. Regarding subgroups, PD-MCI patients scored higher than PD-NC patients on the Lille Apathy Rating Scale [25]. There was no other significant between-group difference. Finally, demographic and clinical characteristics of PD-FS and PD-PC subtypes are presented in **Table 2**. No significant demographic or clinical difference was found between these subtypes.

Cognitive variables

Detailed cognitive performance is provided in **Table 3**. There was no missing data since only complete cases were considered. PD-MCI patients had significantly lower global cognitive efficiency than PD-NC patients. In addition, PD-MCI patients had lower performance than PD-NC patients in all cognitive domains. Most PD-MCI patients had a PD-FS subtype (80%) with similar frequencies of attention/working memory (60%) and executive (65%) deficits (**Figure 2B**). In the PD-PC subtype, 40% of patients had visuospatial deficits, 37% episodic memory deficits and 33% language deficits

(**Figure 2B**). PD-FS and PD-PC cognitive performance is presented in **Table 4**. PD-PC patients had significantly lower global efficiency than PD-FS patients. Finally, PD-PC patients had significantly poorer performance on visuospatial functions, episodic memory and language than PD-FS patients, while there was no significant between-group difference in attention/working memory and executive functions.

Brain structural data

Significant differences between the PD-NC and PD-MCI patients were observed for vertexwise cortical thickness, global average cortical thickness and first-order radiomic analyses. Other analyses did not reveal any significant difference. Furthermore, there was no significant difference between PD-FS and PD-PC subtypes.

Vertex-wise cortical thickness – Vertex-wise comparisons of cortical thickness revealed one significant cluster of cortical thinning in left hemisphere (**Figure 3A**) and two significant clusters in right hemisphere (**Figure 3B**) of PD-MCI patients compared with PD-NC. Details regarding these clusters, including the corresponding areas, are shown in **Table 5**. Besides, there were significant positive correlations between (a) the mean cortical thickness within the cluster #1 and the mean z-score for executive functions ($r_s=0.21$; $p_{FDR}=0.002$) (**Figure 4A**)., and (b) the mean cortical thickness within the cluster #2 and the mean z-score for attention/working memory ($r_s=0.19$; $p_{FDR}=0.003$) and for executive functions ($r_s=0.21$; $p_{FDR}=0.001$) (**Figure 4B-C**).

Global average cortical thickness – PD-MCI patients had significantly lower average cortical thickness in the left hemisphere compared to PD-NC ($p_{FDR}=0.012$) (**Figure 3C**). A tendency was also noticed in the right hemisphere ($p_{FDR}=0.058$) (**Figure 3D**). A significant positive correlation was found

between the mean z-score for executive functions and the average cortical thickness in the left hemisphere ($r_s=0.16$; $p_{FDR}=0.017$) (Figure 4D).

First-order radiomic features – Between-group comparisons of first-order radiomic features revealed significantly higher interquartile range values in the left caudate nucleus ($p_{FDR}=0.006$) (**Figure 3E**) and hippocampus ($p_{FDR}=0.009$) (**Figure 3F**) along with lower kurtosis values in the left hippocampus ($p_{FDR}=0.009$) (**Figure 3G**) of PD-MCI patients compared to PD-NC patients. Finally, significant negative correlations were found between (a) the mean z-score for executive functions and the interquartile range values in the left caudate nucleus ($r_s=-0.21$; $p_{FDR}<0.001$) (**Figure 4E**) and (b) the mean z-score for visuospatial functions and the interquartile range values in the left functions and the interquartile range values in the left hippocampus ($r_s=-0.15$; $p_{FDR}=0.031$) (**Figure 4F**).

DISCUSSION

In this large cohort of PD patients, candidates to STN-DBS, about half had PD-MCI at baseline. Among them, about 20% had posterior cortical deficits, a subtype considered to be at higher risk of developing earlier dementia [16]. Compared to PD-NC, PD-MCI patients had structural cortical and subcortical alterations, namely several clusters of cortical thinning and changes in grey levels distribution of the left caudate nucleus and hippocampus. All these modifications were independent of age, disease duration and severity. However, we found no brain alteration specifically associated with each PD-MCI subtype.

PD-MCI is frequent among candidates for STN-DBS

In the few previous studies, the rate of PD-MCI among candidates to STN-DBS ranged from 23 to 76% [5,9,10]. Two were retrospective and used a neuropsychological test battery that does not comply with current guidelines [9,10]. PD-MCI was defined according to the level I of the MDS

criteria but only one study indicated the used cut-off [5]. Here, PD-MCI was diagnosed according to an adaptation of the MDS consensus criteria-level 2 allowing to define subtypes and with a z-score set at \leq -1. We adopted this cut-off because, in clinical practice, before being screened for STN-DBS, patients are already strongly selected. Namely, patients with severe cognitive impairment are discarded. This cut-off is thus adapted to this specific patient population. Moreover, we have considered heterogeneity of PD-MCI since patients were categorized into two subtypes according to the dual syndrome hypothesis [14]. The PD-FS subtype was the most frequent (80%). Overall cognitive efficiency was significantly lower in PD-PC compared to PD-FS, suggesting that this subtype may need specific attention. As expected, PD-PC performed significantly lower than PD-FS for visuospatial functions, episodic memory and language. However, there was no significant difference between the two PD-MCI subtypes regarding attention/working memory and executive functions. As previously shown, many PD-PC patients have concomitant frontostriatal deficits, i.e., a mixed syndrome [45]. We recently showed that PD patients with posterior cortical deficits, isolated or not, had more abundant and more extensive structural alterations than PD patients with isolated frontostriatal deficits, suggesting that posterior cortical deficits are associated with more advanced degenerative lesions [45].

PD-MCI is associated with structural changes among PD candidates to STN-DBS

Although it was a secondary objective, our study is the first to reveal structural cortical and subcortical alterations in candidates to STN-DBS with PD-MCI. Namely, we found significant cortical thinning in both hemispheres of PD-MCI compared to PD-NC patients. They also had significantly higher interquartile range values in the left caudate nucleus and hippocampus and lower kurtosis values in the left hippocampus. Outside the context of deep brain stimulation, regional brain atrophy has already been reported in PD-MCI compared to PD-NC [46] and healthy controls [47] but results were inconsistent. Few neuroimaging studies have considered cognitive heterogeneity in PD-MCI. Some

reported changes in amnestic PD-MCI compared to healthy controls [48–50]. Again, results were inconsistent. To our knowledge, no previous study has identified grey matter alterations associated with cognitive impairment in candidates to STN-DBS, considering the PD-MCI subtypes. Our results suggest that, even in patients selected for STN-DBS, neurodegeneration is more advanced in PD-MCI than PD-NC.

Cortical thickness analysis revealed several clusters of significant cortical thinning in PD-MCI compared to PD-NC, predominant in the left hemisphere. Moreover, PD-MCI patients displayed lower global average cortical thickness in the left hemisphere compared to PD-NC, suggesting global atrophy. Cortical thinning concerned large associative cortical areas and was mainly associated with deficits in attention/working memory and executive functions whatever the cognitive subtype. These results are consistent with studies showing cortical thinning in temporal, parietal, frontal, and occipital areas in PD-MCI patients compared with PD-NC [38,51,52]. Besides, cortical thinning in some of these regions has been suggested to be a marker of conversion from PD-MCI to PDD in longitudinal studies [53,54]. The follow-up of our cohort is thus essential to provide the meaning of this marker of cortical atrophy in PD-MCI patients selected for STN-DBS, namely if it is a marker of bad cognitive outcome after surgery.

The significant increase in interquartile range values and decrease in kurtosis values of the left caudate nucleus and hippocampus in PD-MCI were the other structural markers revealed by our analyses of radiomic features. Betrouni et al. found significant associations between early cognitive impairment in PD and alteration of texture features in 3DT1 sequences, including the skewness of the left hippocampus [55]. Taken together, these results suggest that structural changes of the left caudate nucleus and hippocampus might play a role in the pathophysiology of PD-MCI in general, and that they might be interesting biomarkers for the cognitive outcome of STN-DBS. Radiomic features were reported as having a better sensitivity than volumes and shapes analysis methods to detect early morphological changes [55]. Interquartile range quantifies the variation of the grey-levels distribution,

while kurtosis quantifies tailedness of the signal distribution. Higher interquartile range and lower kurtosis represent higher heterogeneity of the grey-levels distribution within the subcortical structures. Although they are both thought to reflect biological alterations, it remains difficult to give a pathophysiological interpretation to these features in the absence of a histological study associating biological lesions to radiomic features. To our knowledge, this issue was addressed in a mouse model of Alzheimer's disease, in which the authors showed that the kurtosis of the hippocampus and thalamus was associated with the tau burden in these nuclei in T2 sequences [56]. In a preclinical model of middle cerebral artery transient occlusion, our group found that texture features were correlated with neural density in the hippocampus contralateral to the ischemic area [57].

The MRI analyses did not reveal any significant anatomical differences between the PD-MCI subtypes. This is inconsistent with our hypothesis that specific structural alterations would be associated with PD-MCI subtypes as defined by the dual syndrome hypothesis in PD patients, selected for STN-DBS. Recently, in a study aiming at identifying structural markers of PD-MCI subtypes, our team reported significant changes in radiomics features and more abundant deformation fields in PD-PC compared to PD-FS and PD-NC patients [45]. These discrepancies might be due to the differences in study population, in one hand PD patients selected for STN-DBS with a strong clinical pre-selection, on the other hand, PD patients without specific exclusion criteria, apart moderate to severe dementia. The study population in PREDISTIM was very homogeneous regarding demographic and clinical characteristics, contrary to other cohorts. Cognition was also less variable. This may explain the small rate of PD-PC patients, which might have limited the power of our statistical analyses.

Strengths and limitations of the study

This study was the first to investigate the neuroimaging markers associated with PD-MCI among PD patients, candidates to STN-DBS. A comprehensive cognitive assessment of PD patients that fulfilled MDS guidelines was performed, with at least two tests for each of the five assessed

cognitive domains. Furthermore, we used innovative and sensitive imaging methods such as analyses of shape and radiomic features to explore the structural brain markers. Finally, the effect of potential nuisance variables was highly controlled in our MRI analyses.

Our study also has some limitations. Firstly, only baseline data are reported here and, of course, it will be essential to determine whether PD-MCI influence the long-term outcome of STN-DBS and if the identified MRI alterations are markers of this outcome. However, as it is the first study on such a large multicentric cohort associating cognitive and MRI data, it was worth to communicate these results. Secondly, to be able to distinguish PD-MCI subtypes, we had to adapt the consensus MDS criteria for PD-MCI [11]. Our adapted criteria were stricter since a cognitive domain was considered impaired and the patient as having PD-MCI when two tests in that domain were failed. This introduces a bias by reducing the frequency of PD-MCI compared to the criteria. Thirdly, the small number of subjects in our PD-PC group might have limited the power of our statistical analyses when comparing the PD-MCI subtypes. Fourthly, our data were acquired in multiple centers and were consequently subject to inter-operator variability. However, the center effect was controlled and this multicentric design provided a more representative sample of PD patients, candidates to STN-DBS. Finally, despite multicentric, our study was not international. Therefore, national habits may have influenced selection of patients and may have induced selection bias.

Conclusions and perspectives

Among PD patients, candidates to STN-DBS, a significant proportion has PD-MCI. Cognitive deficits in this subgroup of patients were associated to both cortical and subcortical structural alterations. Follow-up is necessary to determine whether this cognitive status and the associated MRI biomarkers influence STN-DBS outcomes.

ACKNOWLEDGMENTS

We thank all the participants and their families for their cooperation. The authors are grateful for financial support from the France Parkinson charity, French Ministry of Health (National PHRC 2012), support from the French clinical research network NS-Park/F-Crin and the Fédération de la Recherche Clinique du CHU de Lille (with Alain Duhamel, Maeva Kheng, Julien Labreuch, Dominique Deplanque, Edouard Millois, Nolwen Dautrevaux, Victor Laugeais, Maxime Caillier, Aymen Aouni, Pauline Guyon, Francine Niset, Valérie Santraine, Marie Pleuvret, Julie Moutarde and Laetitia Thibault)

Funding: The study was funded by the France Parkinson charity and French Ministry of Health (PHRC National 2012) and promoted by CHU of Lille (coordinated by Pr Devos and Pr Corvol) with the support of the French network NS-Park. This is an ancillary study to protocol 2013-A00193-42; ClinicalTrials.gov: NCT02360683. The research leading to these results has received funding from the program "Investissements d'Avenir" ANR-10-IAIHU-06.

Conflict of interest: None of the authors had a conflict of interest related to the present research.

AUTHORS' ROLES

- 1) Research project: A. Conception, B. Organization, C. Execution;
- 2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique;
- 3) Manuscript: A. Writing of the first draft, B. Review and Critique.

QD: 1B, 1C, 2A, 2B, 3A

- SD: 1C, 2B, 3A
- RV: 1C, 2C, 3B
- RL: 1A, 1B, 2A, 2C, 3B
- NB: 1C, 2B, 2C, 3B
- A-SR: 1B, 3B
- LD: 1A, 1C, 3B

EB, MB, CBC, CD, FEM, FF, AF, CG, EH, JFH, BJ, GK, HK, DM, AM, MM, CM, OR, TR, MT and

- TW: 1C, 3B
- JCC: 1A, 3B

DD: 1A, 1B, 2C, 3B

KD: 1A, 1B, 1C, 2A, 3B

References

Congratulations on the acceptance of your manuscript into JPD. In reviewing your manuscript, I noticed some references that are not properly formatted. Can you please check that all volume numbers are bolded and that all journal names are abbreviated?

[1] Limousin P, Foltynie T (2019) Long-term outcomes of deep brain stimulation in Parkinson disease. *Nat Rev Neurol* **15**, 234–242.

[2] Xie Y, Meng X, Xiao J, Zhang J, Zhang J (2016) Cognitive Changes following Bilateral Deep Brain Stimulation of Subthalamic Nucleus in Parkinson's Disease: A Meta-Analysis. *Biomed Res Int* 2016, 3596415–6.

[3] Tröster AI, Jankovic J, Tagliati M, Peichel D, Okun MS (2017) Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease. *Mov Disord* **32**, 433–440.

[4] Bove F, Fraix V, Cavallieri F, Schmitt E, Lhommée E, Bichon A, Meoni S, Pélissier P, Kistner A, Chevrier E, Ardouin C, Limousin P, Krack P, Benabid AL, Chabardès S, Seigneuret E, Castrioto A, Moro E (2020) Dementia and subthalamic deep brain stimulation in Parkinson disease: A long-term overview. *Neurology* **95**, e384–e392.

[5] Kim H-J, Jeon BS, Paek SH, Lee K-M, Kim J-Y, Lee J-Y, Kim HJ, Yun JY, Kim YE, Yang H-J, Ehm G (2014) Long-term cognitive outcome of bilateral subthalamic deep brain stimulation in Parkinson's disease. *J Neurol* **261**, 1090–1096.

[6] Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, Horak FB, Okun MS, Foote KD, Krack P, Pahwa R, Henderson JM, Hariz MI, Bakay RA, Rezai A, Marks WJ, Moro E, Vitek JL, Weaver FM, Gross RE, DeLong MR (2011) Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues. *Arch Neurol* **68**, 165–165.

[7] Abboud H, Floden D, Thompson NR, Genc G, Oravivattanakul S, Alsallom F, Swa B, Kubu C, Pandya M, Gostkowski M, Cooper S, Machado AG, Fernandez HH (2015) Impact of mild cognitive impairment on outcome following deep brain stimulation surgery for Parkinson's disease. *Parkinsonism Relat Disord* **21**, 249–253.

[8] Park KW, Jo S, Kim MS, Choi N, Jeon SR, Park HK, Kwon K-Y, Lee CS, Chung SJ (2020) Cognitive profile as a predictor of the long-term outcome after deep brain stimulation in Parkinson's disease. *J Neurol Sci* **417**, 117063.

[9] Merola A, Rizzi L, Artusi CA, Zibetti M, Rizzone MG, Romagnolo A, Bernardini A, Lanotte M, Lopiano L (2014) Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients. *J Neurol* **261**, 1745–1751.

[10] Gruber D, Calmbach L, Kühn AA, Krause P, Kopp UA, Schneider G-H, Kupsch A (2019) Longterm outcome of cognition, affective state, and quality of life following subthalamic deep brain stimulation in Parkinson's disease. *J Neural Transm* **126**, 309–318.

[11] Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M (2012) Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. *Mov Disord* **27**, 349–356.

[12] Biundo R, Weis L, Facchini S, Formento-Dojot P, Vallelunga A, Pilleri M, Antonini A (2014) Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia. *Parkinsonism Relat Disord* **20**, 394–399.

[13] Hobson P, Meara J (2015) Mild cognitive impairment in Parkinson's disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort. *Int J Geriatr Psychiatry* **30**, 1048–1055.

[14] Kehagia AA, Barker RA, Robbins TW (2013) Cognitive Impairment in Parkinson's Disease: The Dual Syndrome Hypothesis. *Neurodegener Dis* **11**, 79–92.

[15] Williams-Gray CH, Foltynie T, Brayne CEG, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. *Brain* **130**, 1787–1798.

[16] Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, Barker RA (2013) The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident populationbased cohort. *J Neurol Neurosurg Psychiatry* **84**, 1258–1264.

[17] Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA (2009) The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. *Brain* **132**, 2958–2969.

[18] Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurology Neurosurg Psychiatry* **55**, 181-4.

[19] Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Hilten JJ van, LaPelle N, _Disorder_Society_UPDRS_Revision_Task_Force M (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov Disord* 23, 2129–2170.

[20] Hoehn MM, Yahr MD (1967) Parkinsonism onset, progression, and mortality. *Neurology* **17**, 427–427.

[21] Schwab R, England A (1969) Projection Technique for Evaluating Surgery in Parkinson's Disease. In *Third Symposium on Parkinson's Disease*, FJ G, IML D, eds. Churchill Livingstone, Edinburgh, pp. 152–157.

[22] Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. *Qual Life Res* **4**, 241–248.

[23] Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23, 56-62.

[24] Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32, 50-55.

[25] Sockeel P, Dujardin K, Devos D, Deneve C, Destée A, Defebvre L (2006) The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease. *J Neurol Neurosurg Psychiatry* **77**, 579–584.

[26] Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. *Mov Disord* **25**, 2649–2653.

[27] Dujardin K, Auzou N, Lhommée E, Czernecki V, Dubois B, Fradet A, Maltete D, Meyer M, Pineau F, Schmitt E, Sellal F, Tison F, Vidal T, Azulay J-P, Welter M-L, Corvol J-C, Durif F, Rascol O, network N-P (2016) French consensus procedure for assessing cognitive function in Parkinson's disease. *Rev Neurol* **172**, 696–702.

[28] Goldman JG, Holden S, Ouyang B, Bernard B, Goetz CG, Stebbins GT (2015) Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests? *Mov Disord* **30**, 402–406.

[29] Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* **53**, 695–699.

[30] Operto G, Chupin M, Batrancourt B, Habert M-O, Colliot O, Benali H, Poupon C, Champseix C, Delmaire C, Marie S, Rivière D, Pélégrini-Issac M, Perlbarg V, Trebossen R, Bottlaender M, Frouin V, Grigis A, Orfanos DP, Dary H, Fillon L, Azouani C, Bouyahia A, Fischer C, Edward L, Bouin M, Thoprakarn U, Li J, Makkaoui L, Poret S, Dufouil C, Bouteloup V, Chételat G, Dubois B, Lehéricy S, Mangin J-F, Cointepas Y, Consortium C (2016) CATI: A Large Distributed Infrastructure for the Neuroimaging of Cohorts. *Neuroinformatics* 14, 253–264.

[31] Glasser MF, Sotiropoulos SN, Wilson JA, Coalson TS, Fischl B, Andersson JL, Xu J, Jbabdi S, Webster M, Polimeni JR, Essen DCV, Jenkinson M, Consortium for the W-MH (2013) The minimal preprocessing pipelines for the Human Connectome Project. *Neuroimage* **80**, 105–124.

[32] Manjón JV, Coupé P (2016) volBrain: An Online MRI Brain Volumetry System. *Front Neuroinform* **10**, 30.

[33] Styner M, Oguz I, Xu S, Brechbühler C, Pantazis D, Levitt JJ, Shenton ME, Gerig G (2006) Framework for the Statistical Shape Analysis of Brain Structures using SPHARM-PDM. *Insight J* 242–250.

[34] Vicory J, Pascal L, Hernandez P, Fishbaugh J, Prieto J, Mostapha M, Huang C, Shah H, Hong J, Liu Z, Michoud L, Fillion-Robin J-C, Gerig G, Zhu H, Pizer SM, Styner M, Paniagua B (2018) Shape in Medical Imaging, International Workshop, ShapeMI 2018, Held in Conjunction with MICCAI 2018, Granada, Spain, September 20, 2018, Proceedings. *Lect Notes Comput Sc* **11167**, 65–72.

[35] Griethuysen JJM van, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, Beets-Tan RGH, Fillion-Robin J-C, Pieper S, Aerts HJWL (2017) Computational Radiomics System to Decode the Radiographic Phenotype. *Cancer Res* **77**, e104–e107.

[36] Haralick RM, Shanmugam K, Dinstein I (1973) Textural Features for Image Classification. *Ieee Transactions Syst Man Cybern* SMC-3, 610–621.

[37] Fischl B, Dale AM (2000) Measuring the thickness of the human cerebral cortex from magnetic resonance images. *Proc National Acad Sci* **97**, 11050–11055.

[38] Segura B, Baggio HC, Marti MJ, Valldeoriola F, Compta Y, Garcia-Diaz AI, Vendrell P, Bargallo N, Tolosa E, Junque C (2014) Cortical thinning associated with mild cognitive impairment in Parkinson's disease. *Mov Disord* **29**, 1495–1503.

[39] RCoreTeam (2018) R: A language and environment for statistical computing. *Vienna, Austria: R Foundation for Statistical Computing.*

[40] Frossard J, Renaud O (2019) Permuco: Permutation Tests for Regression, (Repeated Measures) ANOVA/ANCOVA and Comparison of Signals. R Package Version 1.0.0.

[41] Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J Royal Statistical Soc Ser B Methodol* **57**, 289–300.

[42] Kim S (2015) ppcor: An R Package for a Fast Calculation to Semi-partial Correlation Coefficients. *Commun Statistical Appl Methods* **22**, 665–674.

[43] Winkler AM, Ridgway GR, Webster MA, Smith SM, Nichols TE (2014) Permutation inference for the general linear model. *Neuroimage* **92**, 381–397.

[44] Adams D, Collyer M, Kaliontzopoulou A, Baken E Geomorph: Software for geometric morphometric analyses. *R package version 332*.

[45] Devignes Q, Viard R, Betrouni N, Carey G, Kuchcinski G, Defebvre L, Leentjens AFG, Lopes R, Dujardin K (2021) Posterior Cortical Cognitive Deficits Are Associated With Structural Brain Alterations in Mild Cognitive Impairment in Parkinson's Disease. *Front Aging Neurosci* **13**, 668559.

[46] Beyer MK, Janvin CC, Larsen JP, Aarsland D (2007) A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. *J Neurology Neurosurg Psychiatry* **78**, 254-9.

[47] Weintraub D, Doshi J, Koka D, Davatzikos C, Siderowf AD, Duda JE, Wolk DA, Moberg PJ, Xie SX, Clark CM (2011) Neurodegeneration Across Stages of Cognitive Decline in Parkinson Disease. *Arch Neurol* **68**, 1562–1568.

[48] Kawabata K, Watanabe H, Hara K, Bagarinao E, Yoneyama N, Ogura A, Imai K, Masuda M, Yokoi T, Ohdake R, Tanaka Y, Tsuboi T, Nakamura T, Hirayama M, Ito M, Atsuta N, Maesawa S, Naganawa S, Katsuno M, Sobue G (2018) Distinct manifestation of cognitive deficits associate with different resting-state network disruptions in non-demented patients with Parkinson's disease. *J Neurol* **265**, 688–700.

[49] Lee JE, Park H-J, Song SK, Sohn YH, Lee JD, Lee PH (2010) Neuroanatomic basis of amnestic MCI differs in patients with and without Parkinson disease. *Neurology* **75**, 2009–2016.

[50] Chung SJ, Park Y -H., Yun HJ, Kwon H, Yoo HS, Sohn YH, Lee J -M., Lee PH (2019) Clinical relevance of amnestic versus non-amnestic mild cognitive impairment subtyping in Parkinson's disease. *Eur J Neurol* **26**, 766–773.

[51] Pagonabarraga J, Corcuera-Solano I, Vives-Gilabert Y, Llebaria G, García-Sánchez C, Pascual-Sedano B, Delfino M, Kulisevsky J, Gómez-Ansón B (2013) Pattern of Regional Cortical Thinning Associated with Cognitive Deterioration in Parkinson's Disease. *Plos One* **8**, e54980.

[52] Hanganu A, Bedetti C, Jubault T, Gagnon J, Mejia-Constain B, Degroot C, Lafontaine A, Chouinard S, Monchi O (2013) Mild cognitive impairment in patients with Parkinson's disease is associated with increased cortical degeneration. *Mov Disord* **28**, 1360–1369.

[53] Hanganu A, Bedetti C, Degroot C, Mejia-Constain B, Lafontaine A-L, Soland V, Chouinard S, Bruneau M-A, Mellah S, Belleville S, Monchi O (2014) Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally. *Brain* **137**, 1120–1129.

[54] Gasca-Salas C, García-Lorenzo D, Garcia-Garcia D, Clavero P, Obeso JA, Lehericy S, Rodríguez-Oroz MC (2019) Parkinson's disease with mild cognitive impairment: severe cortical thinning antedates dementia. *Brain Imaging Behav* **13**, 180–188.

[55] Betrouni N, Lopes R, Defebvre L, Leentjens AFG, Dujardin K (2020) Texture Features of Magnetic Resonance Images: A Marker of Slight Cognitive Deficits in Parkinson's Disease. *Mov Disord* **35**, 486–494.

[56] Colgan N, Ganeshan B, Harrison IF, Ismail O, Holmes HE, Wells JA, Powell NM, O'Callaghan JM, O'Neill MJ, Murray TK, Ahmed Z, Collins EC, Johnson RA, Groves A, Lythgoe MF (2017) In Vivo Imaging of Tau Pathology Using Magnetic Resonance Imaging Textural Analysis. *Front Neurosci* **11**, 599.

[57] Betrouni N, Yasmina M, Bombois S, Pétrault M, Dondaine T, Lachaud C, Laloux C, Mendyk A-M, Henon H, Bordet R (2020) Texture Features of Magnetic Resonance Images: an Early Marker of Post-stroke Cognitive Impairment. *Transl Stroke Res* **11**, 643–652.

Tables

	All (n=320)	PD-NC (n=167)	PD-MCI (n=153)	<i>p</i> _{FDR} - value	Missing data (%)
DEMOGRAPHICS					
Age (years)	60.03 (7.69)	59.50 (8.29)	60.61 (6.97)	0.62	0 (0.00)
Sex (men/women ratio)	1.74	1.61	1.89	0.57	0 (0.00)
Formal education duration (<12 years/12 years/>12 years) (%)	105 (32.81)/ 53 (16.56)/ 162 (50.63)	44 (26.35)/ 29 (17.37)/ 94 (56.28)	61 (39.87)/ 24 (15.69)/ 68 (44.44)	0.11	0 (0.00)
CLINICAL CHARACTERISTICS					
Disease duration (years)	9.72 (3.85)	9.49 (3.78)	9.97 (3.92)	0.64	0 (0.00)
Age at onset (years)	50.80 (7.57)	50.54 (7.96)	51.09 (7.14)	0.79	0 (0.00)
MDS-UPDRS 3 – score Best ON	9.67 (7.51)	9.90 (7.14)	9.42 (7.91)	0.52	2 (0.63)
MDS-UPDRS 3 – score OFF	39.84 (15.94)	39.92 (16.18)	39.75 (15.71)	0.97	4 (1.25)
Hoehn & Yahr stage – ON	1.25 (0.79)	1.21 (0.77)	1.29 (0.81)	0.72	21 (6.56)
Hoehn & Yahr stage – OFF	2.58 (0.87)	2.50 (0.85)	2.66 (0.88)	1.00	9 (2.81)
Dopa-sensitivity (in %)	76.85 (12.90)	75.99 (12.95)	77.80 (12.83)	0.60	6 (1.88)
Ratio of the dominant side of motor symptoms	0.01 (0.30)	0.05 (0.30)	-0.02 (0.30)	0.77	1 (0.31)
MDS-UPDRS 2 – ON	6.14 (5.98)	6.33 (6.07)	5.94 (5.89)	0.65	8 (2.50)
MDS-UPDRS 4	8.31 (3.73)	8.22 (3.63)	8.41 (3.84)	0.79	0 (0.00)
MDS-UPDRS 1.2 (%)	43 (13.44)	24 (14.37)	19 (12.42)	0.81	8 (2.50)
Schwab & England scale – ON	93.94 (8.59)	93.06 (9.78)	94.93 (6.92)	0.56	18 (5.63)
Schwab & England scale – OFF	69.71 (17.69)	70.55 (17.52)	68.79 (17.89)	0.66	7 (2.19)
PDQ39	51.69 (21.21)	50.02 (19.60)	53.53 (22.77)	0.59	3 (0.94)
MEDICATION					
LEDD (mg/day)	1346.79 (504.98)	1352.98 (483.10)	1339.78 (530.27)	0.82	13 (4.06)
Antipsychotic (%)	9 (2.81)	3 (1.80)	6 (3.92)	1.00	0 (0.00)
Antidepressant (%)	60 (18.75)	28 (16.77)	32 (20.92)	0.80	0 (0.00)
Benzodiazepine (%)	49 (15.31)	24 (14.37)	25 (16.34)	0.87	0 (0.00)
NEUROPSYCHIATRY					
Hamilton depression rating scale (/54)	5.21 (4.11)	5.19 (4.14)	5.22 (4.10)	0.88	0 (0.00)
Hamilton anxiety rating scale (/56)	6.34 (5.39)	6.05 (5.06)	6.66 (5.75)	0.62	16 (5.00)
Lille apathy rating scale (from -36 (no apathy) to 36 (severe apathy))	-28.16 (5.56)	-28.68 (5.83)	-27.58 (5.20)	0.042*	5 (1.56)

Table 1 - Sociodemographic and clinical characteristics of the patient g	groups
--	--------

Mean (standard deviation) is presented for continuous variables and frequency (percentage) for categorical variables. For the dominant side of motor symptoms, a positive score indicates a left dominance and a negative one a right dominance. Results are significant at $*p_{FDR} \le 0.05$. FDR = false discovery rate; LEDD= levodopa equivalent daily dose; MDS-UPDRS 1.2 = Movement Disorder Society – Unified Parkinson's disease Rating Scale, part I, item 2 (hallucination); MDS-UPDRS 3= Movement Disorder Society – Unified Parkinson's disease Rating Scale, part 3 (severity of motor symptoms); PD = Parkinson's disease; PD-MCI = PD-mild cognitive impairment; PD-NC = PD-normal cognition; PDQ39 = Parkinson's disease questionnaire – 39.

	PD-FS (n=123)	PD-PC (n=30)	<i>p</i> FDR-value
DEMOGRAPHICS			
Age (years)	60.08 (6.84)	62.77 (7.17)	0.051
Sex (men/women ratio)	2.00	1.50	0.53
Formal education duration (<12 years/12 years/>12 years) (%)	45 (36.59)/ 18 (14.63)/ 60 (48.78)	16 (53.33)/ 6 (20.00)/ 8 (26.67)	0.13
CLINICAL CHARACTERISTICS			
Disease duration (years)	9.97 (4.03)	10.00 (3.47)	1.00
Age at onset (years)	50.59 (7.05)	53.13 (7.27)	0.28
MDS-UPDRS 3 – score Best ON	9.25 (8.20)	10.14 (6.64)	0.98
MDS-UPDRS 3 – score OFF	39.59 (15.64)	40.40 (16.25)	0.89
Hoehn & Yahr stage – ON	1.34 (0.82)	1.09 (0.75)	0.70
Hoehn & Yahr stage – OFF	2.66 (0.90)	2.67 (0.81)	0.95
Dopa-sensitivity (in %)	78.19 (13.19)	76.16 (11.27)	0.69
MDS-UPDRS 2 – ON	5.74 (5.55)	6.73 (7.15)	1.00
MDS-UPDRS 4	8.29 (3.71)	8.90 (4.37)	1.00
MDS-UPDRS 1.2 (%)	16 (13.01)	3 (10.00)	0.91
Schwab & England scale – ON	94.70 (7.30)	95.93 (5.01)	1.00
Schwab & England scale – OFF	69.01 (17.88)	67.78 (18.26)	1.00
PDQ39	53.70 (23.18)	52.83 (21.40)	0.98
MEDICATION			
LEDD (mg/day)	1312.20 (510.91)	1471.04 (608.53)	0.60
Antipsychotic (%)	6 (4.88)	0 (0.00)	0.80
Antidepressant (%)	26 (21.14)	6 (20.00)	1.00
Benzodiazepine (%)	19 (15.45)	6 (20.00)	1.00
NEUROPSYCHIATRY			
Hamilton depression rating scale (/54)	5.10 (4.31)	5.77 (3.13)	0.45
Hamilton anxiety rating scale (/56)	6.59 (6.10)	6.93 (4.05)	0.38
Lille apathy rating scale (from -36 (no apathy) to 36 (severe apathy))	-27.59 (5.02)	-27.54 (6.00)	0.89

Table 2- Sociodemographic and clinical characteristics for the PD-MCI subtype

Mean (standard deviation) is presented for continuous variables and frequency (percentage) for categorical variables. FDR = false discovery rate; LEDD= levodopa equivalent daily dose; MDS-UPDRS 1.2 = Movement Disorder Society – Unified Parkinson's disease Rating Scale, part 1, item 2 (hallucination); MDS-UPDRS 3= Movement Disorder Society – Unified Parkinson's disease Rating Scale, part 3 (severity of motor symptoms); PD = Parkinson's disease; PD-FS = PD-frontostriatal subtype; PD-PC = PD-posterior cortical subtype.

	All (n=320)	PD-NC (n=167)	PD-MCI (n=153)	<i>p</i> FDR-value
GLOBAL EFFICIENCY				
Montreal Cognitive Assessment – total (/30)	27.24 (1.78)	27.55 (1.74)	26.90 (1.77)	0.008*
ATTENTION/WORKING MEMORY				
WAIS-R – forward digit span (/14)	9.00 (1.95)	9.38 (1.95)	8.58 (1.85)	<0.001*
WAIS-R – backward digit span (/14)	7.37 (2.04)	8.13 (1.98)	6.54 (1.77)	<0.001*
SDMT – correct substitutions in 90 sec	43.79 (9.36)	47.01 (9.65)	40.27 (7.64)	<0.001*
CWIT – denomination time	31.36 (6.33)	28.41 (4.18)	34.58 (6.72)	<0.001*
EXECUTIVE FUNCTIONS				
CWIT – interference time	63.66 (16.20)	56.70 (11.78)	71.26 (16.96)	<0.001*
CWIT – interference errors	1.47 (2.06)	1.02 (1.43)	1.96 (2.50)	<0.001*
CWIT – flexibility time	73.60 (22.18)	65.03 (16.41)	82.95 (23.86)	<0.001*
CWIT – flexibility errors	2.46 (2.76)	1.93 (2.17)	3.04 (3.20)	0.003*
Oral letter-number sequencing task – alternation/base ratio	5.81 (3.86)	4.61 (2.90)	7.12 (4.33)	<0.001*
Oral letter-number sequencing task – alternation errors	0.56 (1.02)	0.39 (0.93)	0.75 (1.07)	0.005*
EPISODIC MEMORY				
16-item FCRT– sum of the 3 free recalls (/48)	30.33 (5.79)	32.13 (5.36)	28.37 (5.62)	<0.001*
16-item FCSRT – sum of the 3 total recalls (/48)	46.27 (2.32)	46.56 (1.95)	45.94 (2.63)	0.048*
10/36 SRT – sum of the 3 first recalls (/30)	14.39 (5.40)	14.84 (5.56)	13.89 (5.19)	0.41
10/36 SRT – delayed recall (/10)	5.24 (2.40)	5.71 (2.41)	4.73 (2.29)	0.007*
VISUOSPATIAL FUNCTIONS				
Benton judgment of line orientation (/15)	12.38 (2.15)	12.86 (1.70)	11.85 (2.44)	<0.001*
CLOX – drawing (/15)	13.11 (1.81)	13.28 (1.61)	12.93 (1.99)	0.27
CLOX – copy (/15)	13.90 (1.10)	13.99 (1.01)	13.80 (1.18)	0.31
LANGUAGE				
Boston naming test (/15)	12.53 (1.97)	12.79 (1.65)	12.24 (2.24)	0.034*
Semantic fluency – number of correct words	21.32 (5.18)	22.32 (4.67)	20.22 (5.48)	0.006*

Table 3 – Cognitive performance of patient groups

Mean (standard deviation) raw score at each cognitive parameter according to PD-MCI subtype. Results are considered significant at $p_{FDR} \le 0.05$. CLOX = clock-drawing test; CWIT = color-word interference test; FCRT = free and cued recall test – 16 items; FDR= false discovery rate; SDMT = symbol digit modalities test; SRT = spatial recall test; WAIS-R= Wechsler's adult intelligence scale – revised.

	PD-FS (n=123)	PD-PC (n=30)	<i>p</i> _{FDR} -value
GLOBAL EFFICIENCY			
Montreal Cognitive Assessment – total (/30)	27.19 (1.70)	25.73 (1.57)	<0.001*
ATTENTION/WORKING MEMORY			
WAIS-R – forward digit span (/14)	8.47 (1.86)	9.00 (1.80)	0.31
WAIS-R – backward digit span (/14)	6.52 (1.70)	6.63 (2.09)	1.00
SDMT – correct substitutions in 90 sec	40.38 (7.31)	39.83 (8.99)	0.75
CWIT – denomination time	34.33 (6.97)	35.60 (5.52)	0.66
EXECUTIVE FUNCTIONS			
CWIT – interference time	70.81 (16.28)	73.10 (19.69)	0.86
CWIT – interference errors	1.79 (2.10)	2.67 (3.66)	0.90
CWIT – flexibility time	82.10 (24.06)	86.47 (23.12)	1.00
CWIT – flexibility errors	2.96 (3.25)	3.37 (2.99)	0.99
Oral letter-number sequencing task – alternation/base ratio	6.99 (4.02)	7.63 (5.47)	1.00
Oral letter-number sequencing task – alternation errors	0.70 (0.97)	0.93 (1.41)	1.00
EPISODIC MEMORY			
16-item FCRT– sum of the 3 free recalls (/48)	29.23 (5.30)	24.83 (5.62)	0.002*
16-item FCRT – sum of the 3 total recalls (/48)	46.52 (1.72)	43.57 (4.08)	<0.001*
10/36 SRT – sum of the 3 first recalls (/30)	14.33 (5.34)	12.10 (4.12)	0.16
10/36 SRT – delayed recall (/10)	5.00 (2.32)	3.63 (1.79)	0.025*
VISUOSPATIAL FUNCTIONS			
Benton judgment of line orientation (/15)	12.20 (2.15)	10.40 (3.01)	0.005*
CLOX – drawing (/15)	13.02 (2.00)	12.53 (1.96)	0.27
CLOX – copy (/15)	13.91 (1.12)	13.33 (1.32)	0.053
LANGUAGE			
Boston naming test (/15)	12.47 (2.21)	11.27 (2.12)	0.023*
Semantic fluency – number of correct words	20.98 (5.27)	17.13 (5.32)	0.007*

 Table 4 – Cognitive performance of the PD-MCI subtypes

Mean (standard deviation) raw score at each cognitive parameter according to PD-MCI subtype. Results are considered significant at **p*FDR<0.05. CLOX = clock-drawing test; CWIT = color-word interference test; FCRT = free and cued recall test – 16 items; FDR= false discovery rate; PD = Parkinson's disease; PD-FS = PD-frontostriatal subtype; PD-PC = PD-posterior cortical subtype; SDMT = symbol digit modalities test; SRT = spatial recall test; WAIS-R= Wechsler's adult intelligence scale – revised.

Cluster label	Cluster	Continal anos	Peak coordinates (MNI152)			Peak t
surface (mm ²)		Cortical area	Cortical area x		Z	(p _{FDR} -values)
#1	37715.1	Left frontal pole, rostral middle frontal, medial orbitofrontal, rostral anterior cingulate, caudal anterior cingulate, superior frontal, paracentral, posterior cingulate, superior parietal, precuneus, isthmus cingulate, cuneus, pericalcarine, lateral occipital, lingual, fusiform, parahippocampal, entorhinal, temporal pole, inferior temporal, pars orbitalis, pars triangularis, pars opercularis, transverse temporal, insula, superior temporal, middle temporal, bankssts, supramarginal, inferior parietal, postcentral, precentral, caudal middle frontal, lateral occipital	-29.76	-36.30	-16.25	4.60 (0.005)
#2	9066.3	Right insula, middle temporal, inferior temporal, fusiform, entorhinal, parahippocampal, superior temporal temporal pole, bankssts, transverse temporal, supramarginal, pars opercularis, pars triangularis, lateral orbitofrontal	38.32	-4.05	-44.70	4.39 (0.029)
#3	111.5	Right pre-central, post-central	32.56	-24.67	68.18	2.27 (0.048)

 $\begin{array}{l} \textbf{Table 5}-\textbf{Characteristics of the significant clusters of cortical thinning in PD-MCI compared to PD-NC \\ \textbf{NC} \end{array}$

Data represent the label and surface (mm²) of each cluster, the corresponding cortical areas in the Freesurfer atlas as well as the coordinates in the MNI152 space, t- and *p*-value of the most significant vertex. Clusters were significant at $p_{FDR}<0.05$. bankssts = banks of the superior temporal sulcus; FDR = false discovery rate; MNI = Montreal Neurological Institute space; PD = Parkinson's disease; PD-MCI = PD-mild cognitive impairment; PD-NC = PD-normal cognition

Figures

Figure 1 – Study flowchart



PREDISTIM = Predictive Factors and Subthalamic Stimulation in Parkinson's Disease; 3DT1 = 3-dimensional T1weighted; MRI = magnetic resonance imaging; PD = Parkinson's disease; PD-FS = PD-frontostriatal subtype; PD-MCI = PD-mild cognitive impairment; PD-NC = PD-normal cognition; PD-PC = PD-posterior cortical subtype.



(A)



A/WM = attention/working memory; EF = executive functions; EM = episodic memory; LAN = language; PD = Parkinson's disease; PD-FS = PD-frontostriatal subtype; PD-PC = PD-posterior cortical subtype; VF = visuospatial functions.



Figure 3 – Significant MRI results for vertex-wise cortical thickness (A-B), global mean cortical thickness (C-D) and radiomic parameters (E-G) according to cognitive status

Significant clusters of cortical thinning in left (A) and right (B) hemispheres of PD-MCI patients compared to PD-NC are represented with $-\log(p_{FDR})$ values ≥ 1.3 . Boxplots of mean cortical thickness (in mm) in left (C) and right (D) hemispheres and of significant radiomic-based parameters in left caudate nucleus (E) and in left hippocampus (F-G) are also represented. Results are significant at $*p_{FDR}\leq 0.05$. FDR = false discovery rate; PD = Parkinson's disease; PD-MCI = PD-mild cognitive impairment; PD-NC = PD-normal cognition.



Figure 4 – Significant correlations between cognitive z-scores and MRI parameters according to PD group

FDR = false discovery rate; PD = Parkinson's disease; PD-MCI = PD-mild cognitive impairment; PD-NC = PD-normal cognition; r_s = Spearman Rho.

PREDISTIM study group

Lille

- Neurologists: Dr Caroline Moreau, Pr Luc Defebvre, Dr Nicolas Carriere, Dr Guillaume Grolez, Dr
 Gillaume Baille, Dr Kreisler
- Neuroradiologists: Pr Jean-Pierre Pruvo, Pr Xavier Leclerc, Dr Renaud Lopes, Dr Romain Viard, Dr
 Gregory Kuchcinski, Mr Julien Dumont
- Neuropsychologists: Pr Kathy Dujardin, Mme M Delliaux, Mme M Brion, Mme Virginie Herlin
- Neurosurgeons: Dr Gustavo Touzet, Pr Nicolas Reyns
- Neurophysiologists: Pr Arnaud Delval
- Clinical Assistant: Mme Valerie Santraine, Mme Marie Pleuvret, Mme Nolwen Dautrevaux, Mr
 Victor Laugeais, Mme Morgane Coeffet
- Clinical trials vigilance unit: Thavarak Ouk, Camille Potey, Celine Leclercq, Elise Gers

Paris

- Neurologists: Jean-Christophe Corvol, Marie-Vidailhet, Elodie Hainque, Marie-Laure Welter, Lucette Lacomblez, David Grabli, Emmanuel Roze, Yulia Worbe, Cécile Delorme, Hana You, Jonas Ihle, Raquel Guimeraes-Costa, Florence Cormier-Dequaire, Aurélie Méneret, Andréas Hartmann, Louise-Laure Mariani
- Neuroradiologists: Stéphane Lehericy
- Neuropsychologists: Virginie Czernecki, Fanny Pineau, Frédérique Bozon, Camille Huiban, Eve Benchetrit, Marie Alexandrine Glachant
- Neurosurgeons: Carine Karachi, Soledad Navarro, Philippe Cornu
- Clinical Assistant: Arlette Welaratne, Carole Dongmo-Kenfack
- Nurses: Lise Mantisi, Nathalie Jarry, Sophie Aix, Carine Lefort

<u>Nantes</u>

- Neurologists: Dr Tiphaine Rouaud, Pr Philippe Damier, Pr Pascal Derkinderen, Dr Anne-Gaelle Corbille
- Neuroradiologists: Dr Elisabeth Calvier-Auffray
- Neuropsychologists: Madame Laetitia Rocher, Madame Anne-Laure Deruet
- Neurosurgeons: Dr Raoul Sylvie, Dr Roualdes Vincent
- Clinical Assistant: Mme Le Dily Séverine

Clermont-Ferrand

- Neurologists: Dr Ana Marques, Dr Berangere Debilly, Pr Franck Durif, Dr Philippe Derost, Dr
 Charlotte Beal
- Neuroradiologists: Carine Chassain
- Neuropsychologists: Laure Delaby, Tiphaine Vidal
- Neurosurgeons: Pr jean Jeacques Lemaire
- Clinical Assistant: Isabelle Rieu, Elodie Durand

Marseille

- Neurologists: Pr Alexandre Eusebio, Pr Jean-Philippe Azulay, Dr Tatiana Witjas, Dr Frédérique
 Fluchère, Dr Stephan Grimaldi
- Neuroradiologists: Pr Nadine Girard
- Neuropsychologists: Eve Benchetrit, Marie Delfini
- Neurosurgeons: Dr Romain Carron, Pr Jean Regis, Dr Giorgio Spatola
- Clinical Assistant: Camille Magnaudet

Poitiers

- Neurologists: Dr Ansquer Solène, Dr Benatru Isabelle, Dr Colin Olivier, Pr Houeto JL
- Neuroradiologists: Pr Guillevin Remy
- Neuropsychologists: Mme Fradet Anne, Mme Anziza Manssouri, Mme Blondeau Sophie
- Neuropsychiatrist: Dr Richard Philippe

- Neurosurgeons: Dr Cam Philippe, Dr Page Philippe, Pr Bataille Benoit
- Clinical Assistant: Mme Rabois Emilie, Mme Guillemain Annie

Rennes

- Neurologists: Dr Drapier Sophie, Dr Frédérique Leh, Dr Alexandre Bonnet, Pr Marc Vérin
- Neuroradiologists: Dr Jean-Christophe Ferré
- Neuropsychologists: Mr Jean François Houvenaghel
- Neurosurgeons: Pr Claire Haegelen
- Clinical Assistant: Mme Francoise Kestens ; Mme Solenn ory

Bordeaux

- Neurologists: Pr Pierre Burbaud, Dr Nathalie Damon-Perriere, Pr Wassilios Meissner, Pr Francois
 Tison, Dr Stéphanie Bannier, Dr Elsa Krim, Pr Dominique Guehl
- Neuroradiologists: Sandrine Molinier-Blossier, Morgan Ollivier, Marion Lacoste
- Neuropsychologists: Nicolas Auzou, Marie Bonnet
- Neurosurgeons: Pr Emmanuel Cuny, Dr Julien Engelhardt
- Clinical Assistant: Olivier Branchard, Clotilde Huet, Julie Blanchard

Toulouse

- Neurologists: Pr Rascol Olivier, Dr Christine Brefel Courbon, Dr Fabienne Ory Magne, Dr Marion
 Simonetta Moreau
- Psychiatric: Pr Christophe Arbus
- Neuroradioligst: Pr Fabrice Bonneville et Dr Jean Albert Lotterie
- Neuropsychologist: Marion Sarrail
- Neurosurgeon: Pr Patrick Chaynes, Pr François Caire
- Clinical Assistant: Estelle Harroch

Rouen

- Neurologists: Pr David Maltete, Dr Romain Lefaucheur, Dr Damien Fetter
- Neuroradiologists: Dr Nicolas Magne
- Neuropsychologists: Mme Sandrine Bioux, Mme Maud Loubeyre, Mme Evangéline Bliaux, Mme
 Dorothée Pouliquen
- Neurosurgeon: Pr Stéphane Derrey
- Nurse: Mme Linda Vernon
- Biologist: Dr Frédéric Ziegler

Strasbourg

- Neurologists: Mathieu Anheim, Ouhaid Lagha-Boukbiza, Christine Tranchant, Odile Gebus, Solveig Montaut
- Neuroradiologists: Stéphane Kremer
- Neuropsychologists: Nadine Longato, Clélie Phillips
- Neurosurgeons: Jimmy Voirin, Marie des Neiges Santin, Dominique Chaussemy
- Psychiatrist: Dr Amaury Mengin

Nice

- Neurologists: Dr Caroline Girodana, Dr Claire Marsé
- Neuroradiologists: Lydiane Mondot
- Psychiatrics: Bruno Giordana, Robin Kardous
- Neuropsychologists: Bernadette Bailet, Héloise Joly
- Neurosurgeons: Denys Fontaine, Dr Aurélie Leplus
- IDE: Amélie Faustini
- Clinical Assistant: Vanessa Ferrier

Amiens

- Neurologists: Pr Pierre Krystkowiak, Dr Mélissa Tir

- Neuroradiologists: Pr Jean-Marc Constans
- Neuropsychologists: Sandrine Wannepain
- Clinician Psychologist: Audrey Seling
- Neurosurgeon: Dr Michel Lefranc
- Clinical Assistant: Stéphanie Blin
- Parkinson coordinator IDE: Béatrice Schuler

Lyon

- Neurologists: Pr Stephane Thobois, Dr Teodor Danaila, Dr Chloe Laurencin
- Neuroradiologists: Pr Yves Berthezene, Dr Roxana Ameli
- Neuropsychologists: Helene Klinger
- Neurosurgeons: Dr Gustavo Polo, Patrick Mertens
- Nurse: A Nunes
- Clinical Assistant: Elise Metereau

Nancy

- Neurologists: Dr Lucie Hopes, Dr Solène Frismand
- Neuroradiologists: Dr Emmanuelle Schmitt
- Neuropsychologists: Mme Mylène Meyer, Mme Céline Dillier
- Neurosurgeon: Pr Sophie Colnat
- Clinical Assistant: Mme Anne Chatelain

Hospital Fondation Rothschild

- Neurologists: Dr Jean- Philippe Brandel, Dr Cécile Hubsch, Dr Patte Karsenti, Dr Marie Lebouteux, Dr Marc Ziegler
- Neuroradiologists: Dr Christine Delmaire, Dr Julien Savatowky
- Neuropsychologists: Mme Juliette Vrillac, Mme Claire Nakache
- Neurosurgeon: Dr Vincent D'Hardemare

- Clinical Assistant: Mr Lhaouas Belamri

Hospital Foch

- Neurologists: Dr Frédérique Bourdain, Dr Vadim Afanassiev, Dr Philippe Graveleau, Dr Cécilia
 Bonnet, Dr Valérie Mesnage, Dr Jarbas Correa Lino Junior
- Neurophysiologist: Dr Camille Decrocq
- Neuroradiologists: Dr Anne Boulin
- Neuropsychologists: Mme Elodie Dupuy, Mme Inès Barre
- Psychiatrics: Dr Bérénice Gardel
- Neurosurgeons: Pr Béchir Jarraya
- Clinical Assistant: Mme Delphine Lopez, Mr Christophe Fruit
- Coordinator: Mme Catherine Ziz

CATI (MRI acquisition management, preprocessing and data management)

David Gay, Robin Bonicel, Fouzia El Mountassir, Clara Fischer, Jean-François Mangin, Marie Chupin, Yann Cointepas

CRB of Lille (Center of Biological Resources)

Bertrand Accart, Patrick Gelé, Florine Fievet, Matthieu Chabel, Virginie Derenaucourt, Loïc Facon, Yanick Tchantchou Njosse, Dominique Deplanque

Data management of Lille

Alain Duhamel, Lynda Djemmane, Florence Duflot